1
|
Zhu YN, Li MY, Chen L, Ding Y, Shi RH. [Efficacy of curative endoscopic submucosal dissection for patients with early cardia and non-cardia gastric cancer]. ZHONGHUA YI XUE ZA ZHI 2024; 104:4316-4322. [PMID: 39667769 DOI: 10.3760/cma.j.cn112137-20240728-01733] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/14/2024]
Abstract
Objective: To analyze the efficacy of curative endoscopic submucosal dissection (ESD) for patients with early cardia and non-cardia gastric cancer. Methods: Clinical data of patients with early gastric cancer who underwent curative ESD treatment in the Department of Gastroenterology, Zhongda Hospital, Southeast University from August 2016 to July 2023 were retrospectively collected. According to the location of lesions and postoperative pathology, the patients were divided into cardia group (early cardia gastric cancer and high-grade intraepithelial neoplasia) and non-cardia group. Follow-up ended in October 2023. Basic clinical information, endoscopy features and histopathological results, postoperative complications and prognosis were compared between the two groups. Kaplan-Meier method was used to present the survival curve and compare the metachronous recurrence-free survival rate and overall survival rate between the two groups. Results: A total of 279 patients were included, including 96 patients in the cardia group (83 males and 13 females), aged [M (Q1, Q3)] 68 (65, 74) years, and 183 patients in the non-cardia group (136 males and 47 females), aged 67 (59, 72) years. The follow-up duration after ESD was 35 (22, 53) months. Differences in postoperative pathological types and lesion invasion depth between the two groups were statistically significant (all P<0.05). The cardia group had the highest proportion of well/moderately differentiated adenocarcinoma [69.8% (67/96)] and T1-M3 invasion depth [58.3% (56/96)], while the non-cardia group had the highest proportion of well/moderately differentiated adenocarcinoma [52.5% (96/183)] and T1-M1 invasion depth [43.2% (79/183)]. The proportion of merging esophageal mucosal lesions [13.5% (13/96) vs 5.5% (10/183)] and deep cystic gastritis [19.8% (19/96) vs 2.7% (5/183)] in the cardia group were higher than those in the non-cardia group (all P<0.05). There were no statistically significant differences in postoperative complication rates [4.2% (4/96) vs 2.2% (4/183)] and mortality rates [1.0% (1/96) vs 2.2% (4/183)] between two groups (all P>0.05). The rate of metachronous recurrence in the cardia group [11.5% (11/96) vs 4.9% (9/183)] was higher than that in the non-cardia group (P=0.044). The 1-year, 3-year, 5-year metachronous recurrence-free survival rates were 97.9%, 89.6%, 79.8% in the cardia group and 100.0%, 96.3%, 92.1% in the non-cardia group, with statistically significant difference (P=0.015); the 1-year, 3-year, 5-year overall survival rates were 100.0%, 100.0%, 97.1% in the cardia group and 99.5%, 98.3%, 98.3% in the non-cardia group, with no statistically significant difference (P=0.597). Conclusion: Compared to the non-cardia group, patients with early cardia gastric cancer treated with curative ESD have a poorer prognosis, with a higher incidence of metachronous recurrence.
Collapse
|
2
|
Ablikim M, Achasov MN, Adlarson P, Ai XC, Aliberti R, Amoroso A, An MR, An Q, Bai Y, Bakina O, Balossino I, Ban Y, Batozskaya V, Begzsuren K, Berger N, Berlowski M, Bertani M, Bettoni D, Bianchi F, Bianco E, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang TT, Chang WL, Che GR, Chelkov G, Chen C, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen YQ, Chen ZJ, Cheng WS, Choi SK, Chu X, Cibinetto G, Coen SC, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding B, Ding XX, Ding Y, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Duan ZH, Egorov P, Fan YL, Fang J, Fang SS, Fang WX, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fritzsch C, Fu CD, Fu JL, Fu Y, Fu YW, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Gramigna S, Greco M, Gu MH, Gu YT, Guan CY, Guan ZL, Guo AQ, Guo LB, Guo MJ, Guo RP, Guo YP, Guskov A, H XT, Han TT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FHH, Heinz CH, Heng YK, Herold C, Holtmann T, Hong PC, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang XT, Huang YP, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Jeong JH, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jia XQ, Jia ZK, Jiang LL, Jiang PC, Jiang SS, Jiang TJ, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kui X, Kabana S, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Khoukaz A, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuessner MK, Kupsc A, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei TT, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li HB, Li HJ, Li HN, Li H, Li JR, Li JS, Li JW, Li KL, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li QX, Li SX, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Li YG, Li ZJ, Li ZX, Liang C, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin DX, Lin T, Liu BJ, Liu BX, Liu C, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu LC, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma JL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Ma YM, Maas FE, Maggiora M, Malde S, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pei YP, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Plura S, Pogodin S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Ruan SN, Salone N, Sarantsev A, Schelhaas Y, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen WH, Shen XY, Shi BA, Shi HC, Shi JL, Shi JY, Shi QQ, Shi RS, Shi X, Song JJ, Song TZ, Song WM, Song YJ, Song YX, Sosio S, Spataro S, Stieler F, Su YJ, Sun GB, Sun GX, Sun H, Sun HK, Sun JF, Sun K, Sun L, Sun SS, Sun T, Sun WY, Sun Y, Sun YJ, Sun YZ, Sun ZT, Tan YX, Tang CJ, Tang GY, Tang J, Tang YA, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian WH, Tian Y, Tian ZF, Uman I, Wang SJ, Wang B, Wang BL, Wang B, Wang CW, Wang DY, Wang F, Wang HJ, Wang HP, Wang JP, Wang K, Wang LL, Wang M, Wang M, Wang S, Wang S, Wang T, Wang TJ, Wang W, Wang W, Wang WP, Wang X, Wang XF, Wang XJ, Wang XL, Wang Y, Wang YD, Wang YF, Wang YH, Wang YN, Wang YQ, Wang Y, Wang Y, Wang Z, Wang ZL, Wang ZY, Wang Z, Wei D, Wei DH, Weidner F, Wen SP, Wenzel CW, Wiedner UW, Wilkinson G, Wolke M, Wollenberg L, Wu C, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu YJ, Wu Z, Xia L, Xian XM, Xiang T, Xiao D, Xiao GY, Xiao H, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu QN, Xu W, Xu WL, Xu XP, Xu YC, Xu ZP, Xu ZS, Yan F, Yan L, Yan WB, Yan WC, Yan XQ, Yang HJ, Yang HL, Yang HX, Yang T, Yang Y, Yang YF, Yang YX, Yang Y, Yang ZW, Yao ZP, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yu XD, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zeng YJ, Zhai XY, Zhai YC, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HQ, Zhang HY, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZL, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng WJ, Zheng YH, Zhong B, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu L, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou JH, Zu J. R(3780) Resonance Interpreted as the 1^{3}D_{1}-Wave Dominant State of Charmonium from Precise Measurements of the Cross Section of e^{+}e^{-}→Hadrons. PHYSICAL REVIEW LETTERS 2024; 133:241902. [PMID: 39750337 DOI: 10.1103/physrevlett.133.241902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/05/2023] [Revised: 10/24/2024] [Accepted: 10/31/2024] [Indexed: 01/04/2025]
Abstract
We report the precise measurements of the cross section of e^{+}e^{-}→hadrons at center-of-mass energies from 3.645 to 3.871 GeV. We thereby perform the most precise study of the cross sections and find a complex system composed of three resonances of R(3760), R(3780), and R(3810). For the first time, we measure the R(3810) electronic width to be (19.4±7.4±12.1) eV. For the R(3760) resonance, we measure the mass to be (3751.9±3.8±2.8) MeV/c^{2}, the total width to be (32.8±5.8±8.7) MeV, and the electronic width to be (184±75±86) eV. For the R(3780) resonance, we measure its mass to be (3778.7±0.5±0.3) MeV/c^{2}, total width to be (20.3±0.8±1.7) MeV, and electronic width to be (265±67±83) eV. Forty-seven years ago, the ψ(3770) resonance was discovered, and was subsequently interpreted as the 1^{3}D_{1}-wave dominant state of charmonium. However, our analysis of the total-hadron cross sections indicates that the ψ(3770) is not a single state, but a complex system composed of the R(3760), R(3780), and R(3810) resonances. Among these, we interpret the R(3780) is a resonance dominated by the 1^{3}D_{1} charmonium state.
Collapse
|
3
|
Yang L, Zhou G, Liu L, Rao S, Wang W, Jin K, Wu F, Fu C, Zeng M, Ding Y. Staging Chronic Hepatitis B Related Liver Fibrosis with Diffusion-weighted MRI-based Virtual Elastography: Comparisons with Serum Fibrosis Indexes. Clin Radiol 2024; 80:106750. [PMID: 39657563 DOI: 10.1016/j.crad.2024.106750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2024] [Revised: 09/27/2024] [Accepted: 11/12/2024] [Indexed: 12/12/2024]
Abstract
AIM To evaluate and compare the diagnostic performance of diffusion-weighted imaging (DWI)-based virtual magnetic resonance (MR) elastography and serum fibrosis indexes for staging liver fibrosis in patients with chronic hepatitis B (CHB). MATERIALS AND METHODS This retrospective study included 145 patients with CHB. Virtual shear modulus (μDiff) was derived from DWI acquisition with b values of 200 and 1500/mm2. Aspartate aminotransferase to platelet ratio index (APRI), fibrosis-4 index (FIB-4), S index, Fibro Q and gamma-glutamyl transpeptidase to platelet ratio (GPR) were calculated. The diagnostic efficacies of μDiff and serum indexes for staging liver fibrosis were compared. RESULTS μDiff, APRI, FIB-4, S index, Fibro Q, and GPR increased as the hepatic fibrosis progressed (r=0.23-0.52, P<0.05). Areas under the curves (AUCs) of μDiff were 0.725, 0.817 and 0.764 for significant fibrosis, advanced fibrosis, and cirrhosis, respectively. μDiff had greater AUC over FIB-4 (0.686) and Fibro Q (0.638) for advanced fibrosis (P<0.05). The AUCs of combination of μDiff with APRI, FIB-4, S index, Fibro Q, and GPR individually were 0.779, 0.772, 0.763, 0.728, and 0.756 for significant fibrosis, 0.856, 0.842, 0.834, 0.831, and 0.834 for advanced fibrosis, 0.811, 0.818, 0.784, 0.835, and 0.788 for cirrhosis, respectively. The AUCs of the combinations were significantly higher than individual serum index for advanced fibrosis and cirrhosis (all P<0.05). CONCLUSION DWI-based virtual MR elastography could estimate liver fibrosis stages in patients with CHB, which outperformed FIB-4 and Fibro Q for advanced fibrosis. The combination of μDiff with each serum index appears superior to individual serum index for advanced fibrosis and cirrhosis.
Collapse
|
4
|
Krivinko JM, Fan P, Sui Z, Happe C, Hensler C, Gilardi J, Ikonomovic MD, McKinney BC, Newman J, Ding Y, Wang L, Sweet RA, MacDonald ML. Age-related loss of large dendritic spines in the precuneus is statistically mediated by proteins which are predicted targets of existing drugs. Mol Psychiatry 2024:10.1038/s41380-024-02817-w. [PMID: 39537705 DOI: 10.1038/s41380-024-02817-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 10/14/2024] [Accepted: 10/28/2024] [Indexed: 11/16/2024]
Abstract
Preservation of dendritic spines is a putative mechanism of protection against cognitive impairment despite development of Alzheimer Disease (AD)-related pathologies. Aging, the chief late-onset AD risk factor, is associated with dendritic spine loss in select brain areas. However, no study to our knowledge has observed this effect in precuneus, an area selectively vulnerable to early accumulation of AD-related pathology. We therefore quantified dendritic spine density in precuneus from 98 subjects without evidence of neurocognitive decline, spanning ages 20-96, and found a significant negative correlation between age and large dendritic spine density. In these same subjects, we conducted liquid chromatography-tandem mass spectrometry of >5000 proteins and identified 203 proteins which statistically mediate the effect of age on large dendritic spine density. Using computational pharmacology, we identified ten drugs which are predicted to target these mediators, informing future studies designed to test their effects on age-related dendritic spine loss and cognitive decline.
Collapse
|
5
|
Hong WJ, Liu CC, Ding Y. [Research progress in the application of virtual artificial intelligence in risk assessment and diagnosis of periodontal disease]. ZHONGHUA KOU QIANG YI XUE ZA ZHI = ZHONGHUA KOUQIANG YIXUE ZAZHI = CHINESE JOURNAL OF STOMATOLOGY 2024; 59:1155-1161. [PMID: 39472097 DOI: 10.3760/cma.j.cn112144-20240117-00027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/20/2024]
Abstract
Periodontal disease is a common and frequently-occurring disease in China. Early detection, diagnosis, and treatment of periodontal disease are of great significance for achieving universal oral health and even systemic health. Artificial intelligence endows machines with the ability to mimic human intelligent behavior, and is commonly used in medical field with both physical and virtual forms. Virtual artificial intelligence empowers traditional experience in the application of periodontal disease risk assessment and diagnosis, with the potential to develop a variety of oral health screening tools. It helps to provide new evidence for the prognosis of periodontal disease, improve the accuracy and efficiency of diagnosis, reduce technical sensitivity and further promote the periodontal treatment transformation from "treatment-oriented" to "prevention-oriented". This paper reviews the current applications and progresses of virtual artificial intelligence in periodontal risk assessment and diagnosis, as well as its limitations, providing ideas for future researches on the application of virtual artificial intelligence in this field.
Collapse
|
6
|
Li X, Ding Y, Zhang C, Lu Y, Li F, Pan W, Guo S, Li J, Zhao B, Zheng J. Correction to: Effcacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study. Adv Ther 2024:10.1007/s12325-024-03059-6. [PMID: 39520660 DOI: 10.1007/s12325-024-03059-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2024]
|
7
|
Deng YX, Hao LL, Ding S, Ding Y, Qiu WJ, Zhang HW, Liang LL, Zhang KC, Yang Y, Wang RF, Gu XF, Han LS. [Analysis of the regional distribution differences of common variations of the MMACHC gene in cblC methylmalonic acidemia patients]. ZHONGHUA ER KE ZA ZHI = CHINESE JOURNAL OF PEDIATRICS 2024; 62:1076-1082. [PMID: 39429080 DOI: 10.3760/cma.j.cn112140-20240408-00250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 10/22/2024]
Abstract
Objective: To analyze regional differences in MMACHC gene variations among patients with cblC-type methylmalonic acidemia (MMA) in China and to explore the relationship between these variations and neonatal screening, biochemical markers and prognosis. Methods: Retrospective case summary. Clinical and laboratory data, including general condition, biochemical markers and genetic analysis, were collected from 1 859 cblC MMA patients from 2005 to 2023. Patients were divided into 7 groups according to their regions: north China, northeast China, east China, central China, south China, southwest China and northwest China. They were also classified into neonatal screening and non-neonatal screening groups. Mann-Whitney U and Kruskal-Wallis tests were used to compare biochemical marker levels. In contrast, the Chi-square test was applied to compare MMACHC gene variant frequencies, neonatal screening proportion, onset age and prognosis between groups. Results: Among 1 859 cases of cblC MMA, 1 019 were male and 840 were female, with a consultation age of 1.0 (0.1, 5.0) month. A total of 1 787 cases carried compound heterozygous or homozygous variants and only 1 variant site was identified in 72 cases. The 10 most frequent variants were c.609G>A (1 238 cases), c.658_660delAAG (343 cases), c.80A>G (284 cases), c.482G>A (239 cases), c.567dupT (191 cases), c.656_658delAGA (131 cases), c.217C>T (109 cases), c.394C>T (105 cases), c.445_446delTG (51 cases) and c.1A>G (50 cases). The frequency of the c.609G>A was the lowest in northwest China (28.8% (44/154), χ²=-18.42, P<0.05). The frequency of the c.567dupT was the most common in southwest China (25.0% (20/80), χ²=71.70, P<0.001) and c.656_658delAGA had the highest frequency in northeast China (9.3% (19/205), χ²=32.08, P<0.001). Non-missense variants (91.2% (62/68), 88.5% (46/52)) and early-onset patients (90.0% (36/40), 94.4% (34/36)) were both more prevalent in southwest and south China (χ²=14.95, 31.69, both P<0.05). The proportion of neonatal screening was the lowest in south China (22.2% (8/36), χ²=98.48, P<0.05), where the mortality rate was the highest (19.1% (4/21), χ²=38.98, P<0.001). East China exhibited the highest frequency of missense variants (21.5% (339/1 579)), the highest proportion of patients identified through neonatal screening (54.5% (465/853)), and a more significant proportion of patients with good prognosis (36.6% (227/621), χ²=14.57, 93.49, 38.98, all P<0.05). In addition, the c.482G>A variant was more frequent in patients diagnosed by neonatal screening compared to those diagnosed by other methods (8.3% (132/1 586) vs. 5.9% (122/2 060), χ²=7.97, P<0.05). Conclusions: The frequency of MMACHC gene variation varies across different regions. The c.609G>A was least frequent in northwest China, c.567dupT was most common in southwest China, and c.656_658delAGA was most prevalent in northeast China. South China had the lowest neonatal screening rate and the highest mortality. At the same time, east China exhibited the highest frequency of missense variants, the highest proportion of patients identified through neonatal screening and the best prognosis. The c.482G>A variant was more frequent in patients diagnosed by neonatal screening compared to those diagnosed by other methods.
Collapse
|
8
|
Li Y, Zhong X, Huang D, Shi Y, Ding Y. Efficacy and safety of oral abrocitinib monotherapy in pityriasis rubra pilaris. J Eur Acad Dermatol Venereol 2024; 38:e920-e922. [PMID: 38553894 DOI: 10.1111/jdv.19992] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2023] [Accepted: 03/11/2024] [Indexed: 10/26/2024]
|
9
|
Ablikim M, Achasov MN, Adlarson P, Afedulidis O, Ai XC, Aliberti R, Amoroso A, An Q, Bai Y, Bakina O, Balossino I, Ban Y, Bao HR, Batozskaya V, Begzsuren K, Berger N, Berlowski M, Bertani M, Bettoni D, Bianchi F, Bianco E, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chai XY, Chang JF, Che GR, Che YZ, Chelkov G, Chen C, Chen CH, Chen C, Chen G, Chen HS, Chen HY, Chen ML, Chen SJ, Chen SL, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen YQ, Chen ZJ, Chen ZY, Choi SK, Cibinetto G, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng CQ, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding B, Ding XX, Ding Y, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du MC, Du SX, Duan YY, Duan ZH, Egorov P, Fan YH, Fang J, Fang J, Fang SS, Fang WX, Fang Y, Fang YQ, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Feng YT, Fritsch M, Fu CD, Fu JL, Fu YW, Gao H, Gao XB, Gao YN, Gao Y, Garbolino S, Garzia I, Ge L, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Gramigna S, Greco M, Gu MH, Gu YT, Guan CY, Guo AQ, Guo LB, Guo MJ, Guo RP, Guo YP, Guskov A, Gutierrez J, Han KL, Han TT, Hanisch F, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Holtmann T, Hong PC, Hou GY, Hou XT, Hou YR, Hou ZL, Hu BY, Hu HM, Hu JF, Hu SL, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang XT, Huang YP, Huang YS, Hussain T, Hölzken F, Hüsken N, In der Wiesche N, Jackson J, Janchiv S, Jeong JH, Ji Q, Ji QP, Ji W, Ji XB, Ji XL, Ji YY, Jia XQ, Jia ZK, Jiang D, Jiang HB, Jiang PC, Jiang SS, Jiang TJ, Jiang XS, Jiang Y, Jiao JB, Jiao JK, Jiao Z, Jin S, Jin Y, Jing MQ, Jing XM, Johansson T, Kabana S, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kavatsyuk M, Ke BC, Khachatryan V, Khoukaz A, Kiuchi R, Kolcu OB, Kopf B, Kuessner M, Kui X, Kumar N, Kupsc A, Kühn W, Lane JJ, Lavezzi L, Lei TT, Lei ZH, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li HB, Li HJ, Li HN, Li H, Li JR, Li JS, Li K, Li KL, Li LJ, Li LK, Li L, Li MH, Li PR, Li QM, Li QX, Li R, Li SX, Li T, Li WD, Li WG, Li X, Li XH, Li XL, Li XY, Li XZ, Li YG, Li ZJ, Li ZY, Liang C, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao YP, Libby J, Limphirat A, Lin CC, Lin DX, Lin T, Liu BJ, Liu BX, Liu C, Liu CX, Liu F, Liu FH, Liu F, Liu GM, Liu H, Liu HB, Liu HH, Liu HM, Liu H, Liu JB, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu LC, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu X, Liu Y, Liu Y, Liu YB, Liu ZA, Liu ZD, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo JR, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma H, Ma HL, Ma JL, Ma LL, Ma LR, Ma MM, Ma QM, Ma RQ, Ma T, Ma XT, Ma XY, Ma YM, Maas FE, MacKay I, Maggiora M, Malde S, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Moses B, Muchnoi NY, Muskalla J, Nefedov Y, Nerling F, Nie LS, Nikolaev IB, Ning Z, Nisar S, Niu QL, Niu WD, Niu Y, Olsen SL, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pei YP, Pelizaeus M, Peng HP, Peng YY, Peters K, Ping JL, Ping RG, Plura S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qiao CF, Qiao XK, Qin JJ, Qin LQ, Qin LY, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu ZH, Redmer CF, Ren KJ, Rivetti A, Rolo M, Rong G, Rosner C, Ruan MQ, Ruan SN, Salone N, Sarantsev A, Schelhaas Y, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shang ZJ, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen WH, Shen XY, Shi BA, Shi H, Shi HC, Shi JL, Shi JY, Shi QQ, Shi SY, Shi X, Song JJ, Song TZ, Song WM, Song YJ, Song YX, Sosio S, Spataro S, Stieler F, Su SS, Su YJ, Sun GB, Sun GX, Sun H, Sun HK, Sun JF, Sun K, Sun L, Sun SS, Sun T, Sun WY, Sun Y, Sun YJ, Sun YZ, Sun ZQ, Sun ZT, Tang CJ, Tang GY, Tang J, Tang M, Tang YA, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian Y, Tian ZF, Uman I, Wan Y, Wang SJ, Wang B, Wang BL, Wang B, Wang DY, Wang F, Wang HJ, Wang HP, Wang JJ, Wang JP, Wang K, Wang LL, Wang M, Wang NY, Wang S, Wang S, Wang T, Wang TJ, Wang W, Wang W, Wang WP, Wang X, Wang XF, Wang XJ, Wang XL, Wang XN, Wang Y, Wang YD, Wang YF, Wang YL, Wang YN, Wang YQ, Wang Y, Wang Y, Wang Z, Wang ZL, Wang ZY, Wang Z, Wei DH, Weidner F, Wen SP, Wen YR, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu C, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu YH, Wu YJ, Wu Z, Xia L, Xian XM, Xiang BH, Xiang T, Xiao D, Xiao GY, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu M, Xu QJ, Xu QN, Xu W, Xu WL, Xu XP, Xu Y, Xu YC, Xu ZS, Yan F, Yan L, Yan WB, Yan WC, Yan XQ, Yang HJ, Yang HL, Yang HX, Yang T, Yang Y, Yang YF, Yang YF, Yang YX, Yang ZW, Yao ZP, Ye M, Ye MH, Yin JH, Yin J, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu MC, Yu T, Yu XD, Yu YC, Yuan CZ, Yuan J, Yuan J, Yuan L, Yuan SC, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng SH, Zeng X, Zeng Y, Zeng YJ, Zeng YJ, Zhai XY, Zhai YC, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang H, Zhang HC, Zhang HH, Zhang HH, Zhang HQ, Zhang HR, Zhang HY, Zhang J, Zhang J, Zhang JJ, Zhang JL, Zhang JQ, Zhang JS, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang LM, Zhang L, Zhang P, Zhang QY, Zhang RY, Zhang SH, Zhang S, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang Y, Zhang YT, Zhang YH, Zhang YM, Zhang Y, Zhang ZD, Zhang ZH, Zhang ZL, Zhang ZY, Zhang ZY, Zhang ZZ, Zhao G, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao N, Zhao RP, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng BM, Zheng JP, Zheng WJ, Zheng YH, Zhong B, Zhong X, Zhou H, Zhou JY, Zhou LP, Zhou S, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhou ZC, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu KS, Zhu L, Zhu LX, Zhu SH, Zhu TJ, Zhu WD, Zhu YC, Zhu ZA, Zou JH, Zu J. Study of the Decay and Production Properties of D_{s1}(2536) and D_{s2}^{*}(2573). PHYSICAL REVIEW LETTERS 2024; 133:171903. [PMID: 39530816 DOI: 10.1103/physrevlett.133.171903] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/10/2024] [Revised: 08/28/2024] [Accepted: 09/27/2024] [Indexed: 11/16/2024]
Abstract
The e^{+}e^{-}→D_{s}^{+}D_{s1}(2536)^{-} and e^{+}e^{-}→D_{s}^{+}D_{s2}^{*}(2573)^{-} processes are studied using data samples collected with the BESIII detector at center-of-mass energies from 4.530 to 4.946 GeV. The absolute branching fractions of D_{s1}(2536)^{-}→D[over ¯]^{*0}K^{-} and D_{s2}^{*}(2573)^{-}→D[over ¯]^{0}K^{-} are measured for the first time to be (35.9±4.8±3.5)% and (37.4±3.1±4.6)%, respectively. The e^{+}e^{-}→D_{s}^{+}D_{s1}(2536)^{-} and e^{+}e^{-}→D_{s}^{+}D_{s2}^{*}(2573)^{-} cross sections are measured, and a resonant structure at around 4.6 GeV with a width of 50 MeV is observed in both processes with a statistical significance of 7.2σ and 15σ, respectively. The state is observed for the first time in e^{+}e^{-}→D_{s}^{+}D_{s2}^{*}(2573)^{-} and could be the Y(4626) found by the Belle oration in the D_{s}^{+}D_{s1}(2536)^{-} final state, since they have similar masses and widths. There is also evidence for a structure at around 4.75 GeV in both processes.
Collapse
|
10
|
Zhang J, Ding Y, Wang P, Li L, Pan W, Lu Y, Cheng H, Jiang X, Ho JC, Guo S, Liu L, Chatterjee A, Kisa RM, Banerjee S. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in patients from China mainland, Taiwan, and South Korea with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. Br J Dermatol 2024:ljae406. [PMID: 39437312 DOI: 10.1093/bjd/ljae406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2024] [Revised: 09/13/2024] [Accepted: 10/20/2024] [Indexed: 10/25/2024]
Abstract
BACKGROUND Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, is approved in the United States, European Union, Japan, South Korea, China, and other countries for treatment of moderate-to-severe plaque psoriasis. OBJECTIVE To evaluate the efficacy and safety of deucravacitinib in Asian patients with moderate to severe plaque psoriasis. METHODS In the 52-week, blinded, phase 3 POETYK PSO-3 trial (NCT04167462), patients were randomized 1 : 2 to placebo (n = 74) or deucravacitinib 6 mg once daily (n = 146) for 16 weeks followed by deucravacitinib alone. Coprimary endpoints were achievement of ≥ 75% reduction from baseline in Psoriasis Area and Severity Index (PASI 75) and static Physician Global Assessment score of 0 (clear) or 1 (almost clear) (sPGA 0/1) at Week 16. Efficacy and safety were evaluated throughout. RESULTS At Week 16, significantly higher proportions of patients receiving deucravacitinib versus placebo achieved PASI 75 (68.8% vs. 8.1%; P < 0.0001) and sPGA 0/1 (55.6% vs. 6.8%; P < 0.0001). Response rates with deucravacitinib were maintained through Week 52. Common adverse events included upper respiratory tract infection and nasopharyngitis. Serious adverse event and discontinuation rates were low. CONCLUSIONS Deucravacitinib was efficacious and well tolerated in Asian patients with moderate to severe plaque psoriasis.
Collapse
|
11
|
Ablikim M, Achasov MN, Adlarson P, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai Y, Bakina O, Ferroli RB, Balossino I, Ban Y, Batozskaya V, Becker D, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bianco E, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Che GR, Chelkov G, Chen C, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen ZJ, Cheng WS, Choi SK, Chu X, Cibinetto G, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Duan ZH, Egorov P, Fan YL, Fang J, Fang SS, Fang WX, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fritzsch C, Fu CD, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Jang E, Jeong JH, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jia ZK, Jiang PC, Jiang SS, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kabana S, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei TT, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JQ, Li JS, Li JW, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li SX, Li SY, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Li YG, Li ZX, Li ZY, Liang C, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin CX, Lin DX, Lin T, Liu BJ, Liu C, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pei YP, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Plura S, Pogodin S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Ruan SN, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen WH, Shen XY, Shi BA, Shi HC, Shi JY, Shi QQ, Shi RS, Shi X, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su PP, Su YJ, Sun GX, Sun H, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun YJ, Sun YZ, Sun ZT, Tan YX, Tang CJ, Tang GY, Tang J, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian Y, Uman I, Wang B, Wang B, Wang BL, Wang CW, Wang DY, Wang F, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang S, Wang T, Wang TJ, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YH, Wang YQ, Wang Y, Wang Z, Wang ZY, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu YJ, Wu Z, Xia L, Xiang T, Xiao D, Xiao GY, Xiao H, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu XP, Xu YC, Xu ZP, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HL, Yang HX, Yang SL, Yang T, Yang YF, Yang YX, Yang Y, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu T, Yu XD, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zhai XY, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HQ, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZL, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng WJ, Zheng YH, Zhong B, Zhong C, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou JH, Zu J. Extracting the femtometer structure of strange baryons using the vacuum polarization effect. Nat Commun 2024; 15:8812. [PMID: 39394218 PMCID: PMC11470094 DOI: 10.1038/s41467-024-51802-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2023] [Accepted: 08/19/2024] [Indexed: 10/13/2024] Open
Abstract
One of the fundamental goals of particle physics is to gain a microscopic understanding of the strong interaction. Electromagnetic form factors quantify the structure of hadrons in terms of charge and magnetization distributions. While the nucleon structure has been investigated extensively, data on hyperons are still scarce. It has recently been demonstrated that electron-positron annihilations into hyperon-antihyperon pairs provide a powerful tool to investigate their inner structure. We present a method useful for hyperon-antihyperon pairs of different types which exploits the cross section enhancement due to the effect of vacuum polarization at the J/ψ resonance. Using the 10 billion J/ψ events collected with the BESIII detector, this allows a precise determination of the hyperon structure function. The result is essentially a precise snapshot of theΛ ¯ Σ 0 ( Λ Σ ¯ 0 ) transition process, encoded in the transition form factor ratio and phase. Their values are measured to be R = 0.860 ± 0.029(stat.) ± 0.015(syst.), Δ Φ Λ ¯ Σ 0 = ( 1.011 ± 0.094 ( stat. ) ± 0.010 ( syst. ) ) r a d and Δ Φ Λ Σ ¯ 0 = ( 2.128 ± 0.094 ( stat. ) ± 0.010 ( syst. ) ) r a d . Furthermore, charge-parity (CP) breaking is investigated in this reaction and found to be consistent with CP symmetry.
Collapse
Grants
- The BESIII collaboration thanks the staff of BEPCII and the IHEP computing center for their strong support. This work is supported in part by National Key R&D Program of China under Contracts Nos. 2020YFA0406300, 2020YFA0406400; National Natural Science Foundation of China (NSFC) under Contracts Nos. 11635010, 11735014, 11835012, 11875115, 11935015, 11935016, 11935018, 11961141012, 12022510, 12025502, 12035009, 12035013, 12075250, 12165022, 12192260, 12192261, 12192262, 12192263, 12192264, 12192265, 12225509; the Chinese Academy of Sciences (CAS) Large-Scale Scientific Facility Program; Joint Large-Scale Scientific Facility Funds of the NSFC and CAS under Contract No. U1832207; the CAS Center for Excellence in Particle Physics (CCEPP); 100 Talents Program of CAS; The Institute of Nuclear and Particle Physics (INPAC) and Shanghai Key Laboratory for Particle Physics and Cosmology; Yunnan Fundamental Research Project under Contract No. 202301AT070162; ERC under Contract No. 758462; European Union's Horizon 2020 research and innovation programme under Marie Sklodowska-Curie grant agreement under Contract No. 894790; German Research Foundation DFG under Contracts Nos. 443159800, 455635585, Collaborative Research Center CRC 1044, FOR5327, GRK 2149; Istituto Nazionale di Fisica Nucleare, Italy; Ministry of Development of Turkey under Contract No. DPT2006K-120470; National Science and Technology fund; National Science Research and Innovation Fund (NSRF) via the Program Management Unit for Human Resources & Institutional Development, Research and Innovation under Contract No. B16F640076; Olle Engkvist Foundation under Contract No. 200-0605; STFC (United Kingdom); Suranaree University of Technology (SUT), Thailand Science Research and Innovation (TSRI), and National Science Research and Innovation Fund (NSRF) under Contract No. 160355; Polish National Science Centre under Contract 2019/35/O/ST2/02907; The Royal Society, UK under Contracts Nos. DH140054, DH160214; The Knut and Alice Wallenberg Foundation (Sweden); The Swedish Research Council; The Swedish Foundation for International Cooperation in Research and Higher Education (STINT); U. S. Department of Energy under Contract No. DE-FG02-05ER41374.
Collapse
|
12
|
Wu M, Yu Y, Huang D, Wang K, Ding Y, Zhang Y, Shi Y, Zhu X. The Family Dermatology Life Quality Index of Spouses of Patients With Psoriasis: A Cross-Sectional Study. Ann Dermatol 2024; 36:322-325. [PMID: 39343760 PMCID: PMC11439977 DOI: 10.5021/ad.23.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2023] [Revised: 10/11/2023] [Accepted: 10/18/2023] [Indexed: 10/01/2024] Open
|
13
|
Li X, Ding Y, Zhang C, Lu Y, Li F, Pan W, Guo S, Li J, Zhao B, Zheng J. Efficacy of Ixekizumab in Chinese Patients with Moderate-to-Severe Psoriasis and Special Body Area Involvement: Sub-analysis of a Randomized, Double-Blind, Multicenter Phase 3 Study. Adv Ther 2024:10.1007/s12325-024-02976-w. [PMID: 39347926 DOI: 10.1007/s12325-024-02976-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2024] [Accepted: 08/20/2024] [Indexed: 10/01/2024]
Abstract
INTRODUCTION Special body area involvement is common in psoriasis and can be challenging to treat. We investigated the efficacy of ixekizumab (IXE) in Chinese patients with moderate-to-severe psoriasis and fingernail, scalp, or palmoplantar involvement. METHODS A post-hoc sub-analysis of a phase 3 trial, in which patients were randomized to receive placebo, IXE 80 mg every 2 (IXE Q2W) or 4 (IXE Q4W) weeks. At Week 12, patients classified as IXE responders [static Physician's Global Assessment (sPGA) score of 0 or 1 [0,1)] were re-randomized (2:1) to IXE Q4W or placebo until Week 60. Efficacy was assessed by body-region specific parameters including Nail Psoriasis Severity Index (NAPSI), Psoriasis Scalp Severity Index (PSSI), and Palmoplantar Psoriasis Area Severity Index (PPASI). RESULTS Of 438 patients, 99.1% (434) had ≥ 1 special area involvement [fingernail (76.5%, 335), scalp (97.3%, 426), palmoplantar (27.9%, 122)]. Significantly greater improvements from baseline in NAPSI score were observed with IXE Q4W and Q2W at Week 12 versus placebo (p < 0.001 for both). These improvements were further increased and sustained over 60 weeks in IXE Q4W and Q2W responders who were re-randomized to IXE Q4W, who achieved a 77.9% and 89.7% improvement from baseline, respectively, at Week 60. Significantly higher proportions of patients receiving IXE Q4W and Q2W achieved NAPSI 50 at Week 12 versus placebo (44.4%, 36.6% vs. 14.1%; p < 0.001 and < 0.01, respectively). Similarly, significantly higher proportions of patients receiving IXE Q4W and Q2W achieved PSSI 100 and PPASI 100 at Week 12 versus placebo (60.6% and 65.1% vs. 1.2%, and 67.4%, 84.3% vs. 21.4%, respectively; p < 0.001 for all comparisons). Improvements across all outcomes were sustained in patients re-randomized to IXE Q4W until Week 60. CONCLUSION IXE led to a rapid onset of action and sustained efficacy over 60 weeks in Chinese patients with moderate-to-severe psoriasis and special body area involvement. CLINICALTRIALS gov identifier, NCT03364309.
Collapse
|
14
|
Sun JF, Wang XL, Yu WN, Pan SY, Ding Y, Dai HH, Wang XL. [Efficacy and safety of dienogest on ovarian endometrioma]. ZHONGHUA FU CHAN KE ZA ZHI 2024; 59:692-701. [PMID: 39313421 DOI: 10.3760/cma.j.cn112141-20240516-00282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 09/25/2024]
Abstract
Objective: To observe the effects and safety of dienogest on the volume and symptoms of ovarian endometrioma (OMA). Methods: The clinical data of 75 patients with OMA who underwent treatment with dienogest (2 mg/day) at the First Affiliated Hospital of Nanjing Medical University from July 1st 2020 to March 31st 2024 were retrospectively analysed, mainly comparing the changes in the volume of OMA and the visual analogue scale (VAS) scores of endometriosis-related pain before and after the treatment, as well as observing the changes in the blood biological indicators, liver and kidney function, coagulation function and changes in breast. Results: The median cyst volumes of the OMA patients at 3, 6 and 12 months of dienogest treatment were 13.21 cm3 (volume reduction rate: 36.00%), 8.33 cm3 (volume reduction rate: 56.00%) and 4.10 cm3 (volume reduction rate: 77.62%), respectively, which were all significantly decreased from the pre-treatment period (all P<0.05). The VAS scores of pain of the OMA patients at 3, 6 and 12 months of dienogest treatment all were 0 mm. Blood cancer antigen 125 (CA125) and cancer antigen 19-9 (CA19-9) levels decreased progressively during treatment (all P<0.05). There were no statistical differences in the coagulation indexes, liver and kidney function indexes of the patients during dienogest treatment compared with those before treatment (all P>0.05). During the follow-up period, there were a few patients with changes in the growth sites or lesion category of the breast nodules, but there were no occurrence of breast cancer or precancerous lesions. Conclusion: Dienogest is effective in reducing OMA volume and alleviating endometriosis-related pain with few adverse effects.
Collapse
|
15
|
Ablikim M, Achasov MN, Adlarson P, Afedulidis O, Ai XC, Aliberti R, Amoroso A, An Q, Bai Y, Bakina O, Balossino I, Ban Y, Bao HR, Batozskaya V, Begzsuren K, Berger N, Berlowski M, Bertani M, Bettoni D, Bianchi F, Bianco E, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Che GR, Chelkov G, Chen C, Chen CH, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SL, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen YQ, Chen ZJ, Chen ZY, Choi SK, Chu X, Cibinetto G, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng CQ, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding B, Ding XX, Ding Y, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du MC, Du SX, Duan ZH, Egorov P, Fan YH, Fang J, Fang J, Fang SS, Fang WX, Fang Y, Fang YQ, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Feng YT, Fischer K, Fritsch M, Fu CD, Fu JL, Fu YW, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Gramigna S, Greco M, Gu MH, Gu YT, Guan CY, Guan ZL, Guo AQ, Guo LB, Guo MJ, Guo RP, Guo YP, Guskov A, Gutierrez J, Han KL, Han TT, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Holtmann T, Hong PC, Hou GY, Hou XT, Hou YR, Hou ZL, Hu BY, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang XT, Huang YP, Huang ZY, Hussain T, Hölzken F, Hüsken N, In der Wiesche N, Irshad M, Jackson J, Janchiv S, Jeong JH, Ji Q, Ji QP, Ji W, Ji XB, Ji XL, Ji YY, Jia XQ, Jia ZK, Jiang D, Jiang HB, Jiang PC, Jiang SS, Jiang TJ, Jiang XS, Jiang Y, Jiao JB, Jiao JK, Jiao Z, Jin S, Jin Y, Jing MQ, Jing XM, Johansson T, Kabana S, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kavatsyuk M, Ke BC, Khachatryan V, Khoukaz A, Kiuchi R, Kolcu OB, Kopf B, Kuessner M, Kui X, Kupsc A, Kühn W, Lane JJ, Larin P, Lavezzi L, Lei TT, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li HB, Li HJ, Li HN, Li H, Li JR, Li JS, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li QM, Li QX, Li R, Li SX, Li T, Li WD, Li WG, Li X, Li XH, Li XL, Li X, Li YG, Li ZJ, Li ZX, Liang C, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Liao YP, Libby J, Limphirat A, Lin DX, Lin T, Liu BJ, Liu BX, Liu C, Liu CX, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu LC, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu X, Liu XY, Liu Y, Liu Y, Liu YB, Liu ZA, Liu ZD, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma H, Ma HL, Ma JL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma XT, Ma XY, Ma Y, Ma YM, Maas FE, Maggiora M, Malde S, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Moses B, Muchnoi NY, Muskalla J, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu QL, Niu WD, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pei YP, Pelizaeus M, Peng HP, Peng YY, Peters K, Ping JL, Ping RG, Plura S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qiao CF, Qin JJ, Qin LQ, Qin XS, Qin ZH, Qiu JF, Qu SQ, Qu ZH, Redmer CF, Ren KJ, Rivetti A, Rolo M, Rong G, Rosner C, Ruan SN, Salone N, Sarantsev A, Schelhaas Y, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen WH, Shen XY, Shi BA, Shi HC, Shi JL, Shi JY, Shi QQ, Shi RS, Shi SY, Shi X, Song JJ, Song TZ, Song WM, Song YJ, Sosio S, Spataro S, Stieler F, Su YJ, Sun GB, Sun GX, Sun H, Sun HK, Sun JF, Sun K, Sun L, Sun SS, Sun T, Sun WY, Sun Y, Sun YJ, Sun YZ, Sun ZQ, Sun ZT, Tang CJ, Tang GY, Tang J, Tang YA, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian Y, Tian ZF, Uman I, Wan Y, Wang SJ, Wang B, Wang BL, Wang B, Wang DY, Wang F, Wang HJ, Wang JP, Wang K, Wang LL, Wang M, Wang M, Wang NY, Wang S, Wang S, Wang T, Wang TJ, Wang W, Wang W, Wang WP, Wang X, Wang XF, Wang XJ, Wang XL, Wang XN, Wang Y, Wang YD, Wang YF, Wang YL, Wang YN, Wang YQ, Wang Y, Wang Y, Wang Z, Wang ZL, Wang ZY, Wang Z, Wei D, Wei DH, Weidner F, Wen SP, Wen YR, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu C, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu YH, Wu YJ, Wu Z, Xia L, Xian XM, Xiang BH, Xiang T, Xiao D, Xiao GY, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu QN, Xu W, Xu WL, Xu XP, Xu YC, Xu ZP, Xu ZS, Yan F, Yan L, Yan WB, Yan WC, Yan XQ, Yang HJ, Yang HL, Yang HX, Yang T, Yang Y, Yang YF, Yang YX, Yang Y, Yang ZW, Yao ZP, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yu XD, Yuan CZ, Yuan J, Yuan L, Yuan SC, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng SH, Zeng X, Zeng Y, Zeng YJ, Zeng YJ, Zhai XY, Zhai YC, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang HC, Zhang HH, Zhang HH, Zhang HQ, Zhang HY, Zhang J, Zhang J, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang LM, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang YM, Zhang Y, Zhang Y, Zhang ZD, Zhang ZH, Zhang ZL, Zhang ZY, Zhang ZY, Zhao G, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao RP, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng WJ, Zheng YH, Zhong B, Zhong X, Zhou H, Zhou JY, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu L, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou JH, Zu J. Search for Rare Decays of D_{s}^{+} to Final States π^{+}e^{+}e^{-}, ρ^{+}e^{+}e^{-}, π^{+}π^{0}e^{+}e^{-}, K^{+}π^{0}e^{+}e^{-}, and K_{S}^{0}π^{+}e^{+}e^{-}. PHYSICAL REVIEW LETTERS 2024; 133:121801. [PMID: 39373421 DOI: 10.1103/physrevlett.133.121801] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/09/2024] [Accepted: 06/21/2024] [Indexed: 10/08/2024]
Abstract
Using 7.33 fb^{-1} of e^{+}e^{-} collision data collected by the BESIII detector at center-of-mass energies in the range of sqrt[s]=4.128-4.226 GeV, we search for the rare decays D_{s}^{+}→h^{+}(h^{0})e^{+}e^{-}, where h represents a kaon or pion. By requiring the e^{+}e^{-} invariant mass to be consistent with a ϕ(1020), 0.98
Collapse
|
16
|
Ablikim M, Achasov MN, Adlarson P, Afedulidis O, Ai XC, Aliberti R, Amoroso A, An Q, Bai Y, Bakina O, Balossino I, Ban Y, Bao HR, Batozskaya V, Begzsuren K, Berger N, Berlowski M, Bertani M, Bettoni D, Bianchi F, Bianco E, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Che GR, Chelkov G, Chen C, Chen CH, Chen C, Chen G, Chen HS, Chen HY, Chen ML, Chen SJ, Chen SL, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen YQ, Chen ZJ, Chen ZY, Choi SK, Cibinetto G, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng CQ, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding B, Ding XX, Ding Y, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du MC, Du SX, Duan YY, Duan ZH, Egorov P, Fan YH, Fang J, Fang J, Fang SS, Fang WX, Fang Y, Fang YQ, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Feng YT, Fritsch M, Fu CD, Fu JL, Fu YW, Gao H, Gao XB, Gao YN, Gao Y, Garbolino S, Garzia I, Ge L, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Gramigna S, Greco M, Gu MH, Gu YT, Guan CY, Guo AQ, Guo LB, Guo MJ, Guo RP, Guo YP, Guskov A, Gutierrez J, Han KL, Han TT, Hanisch F, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Holtmann T, Hong PC, Hou GY, Hou XT, Hou YR, Hou ZL, Hu BY, Hu HM, Hu JF, Hu SL, Hu T, Hu Y, Hu ZM, Huang GS, Huang KX, Huang LQ, Huang XT, Huang YP, Huang YS, Hussain T, Hölzken F, Hüsken N, In der Wiesche N, Jackson J, Janchiv S, Jeong JH, Ji Q, Ji QP, Ji W, Ji XB, Ji XL, Ji YY, Jia XQ, Jia ZK, Jiang D, Jiang HB, Jiang PC, Jiang SS, Jiang TJ, Jiang XS, Jiang Y, Jiao JB, Jiao JK, Jiao Z, Jin S, Jin Y, Jing MQ, Jing XM, Johansson T, Kabana S, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kavatsyuk M, Ke BC, Khachatryan V, Khoukaz A, Kiuchi R, Kolcu OB, Kopf B, Kuessner M, Kui X, Kumar N, Kupsc A, Kühn W, Lane JJ, Lavezzi L, Lei TT, Lei ZH, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li HB, Li HJ, Li HN, Li H, Li JR, Li JS, Li K, Li KL, Li LJ, Li LK, Li L, Li MH, Li PR, Li QM, Li QX, Li R, Li SX, Li T, Li WD, Li WG, Li X, Li XH, Li XL, Li XY, Li XZ, Li YG, Li ZJ, Li ZY, Liang C, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao YP, Libby J, Limphirat A, Lin CC, Lin DX, Lin T, Liu BJ, Liu BX, Liu C, Liu CX, Liu F, Liu FH, Liu F, Liu GM, Liu H, Liu HB, Liu HH, Liu HM, Liu H, Liu JB, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu LC, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu X, Liu Y, Liu Y, Liu YB, Liu ZA, Liu ZD, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo JR, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma H, Ma HL, Ma JL, Ma LL, Ma LR, Ma MM, Ma QM, Ma RQ, Ma T, Ma XT, Ma XY, Ma Y, Ma YM, Maas FE, Maggiora M, Malde S, Malik QA, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Moses B, Muchnoi NY, Muskalla J, Nefedov Y, Nerling F, Nie LS, Nikolaev IB, Ning Z, Nisar S, Niu QL, Niu WD, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pei YP, Pelizaeus M, Peng HP, Peng YY, Peters K, Ping JL, Ping RG, Plura S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qiao CF, Qiao XK, Qin JJ, Qin LQ, Qin LY, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu ZH, Redmer CF, Ren KJ, Rivetti A, Rolo M, Rong G, Rosner C, Ruan SN, Salone N, Sarantsev A, Schelhaas Y, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shang ZJ, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen WH, Shen XY, Shi BA, Shi H, Shi HC, Shi JL, Shi JY, Shi QQ, Shi SY, Shi X, Song JJ, Song TZ, Song WM, Song YJ, Song YX, Sosio S, Spataro S, Stieler F, Su SS, Su YJ, Sun GB, Sun GX, Sun H, Sun HK, Sun JF, Sun K, Sun L, Sun SS, Sun T, Sun WY, Sun Y, Sun YJ, Sun YZ, Sun ZQ, Sun ZT, Tang CJ, Tang GY, Tang J, Tang M, Tang YA, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian Y, Tian ZF, Uman I, Wan Y, Wang SJ, Wang B, Wang BL, Wang B, Wang DY, Wang F, Wang HJ, Wang JJ, Wang JP, Wang K, Wang LL, Wang M, Wang NY, Wang S, Wang S, Wang T, Wang TJ, Wang W, Wang W, Wang WP, Wang X, Wang XF, Wang XJ, Wang XL, Wang XN, Wang Y, Wang YD, Wang YF, Wang YL, Wang YN, Wang YQ, Wang Y, Wang Y, Wang Z, Wang ZL, Wang ZY, Wang Z, Wei DH, Weidner F, Wen SP, Wen YR, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu C, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu YH, Wu YJ, Wu Z, Xia L, Xian XM, Xiang BH, Xiang T, Xiao D, Xiao GY, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu M, Xu QJ, Xu QN, Xu W, Xu WL, Xu XP, Xu Y, Xu YC, Xu ZS, Yan F, Yan L, Yan WB, Yan WC, Yan XQ, Yang HJ, Yang HL, Yang HX, Yang T, Yang Y, Yang YF, Yang YF, Yang YX, Yang ZW, Yao ZP, Ye M, Ye MH, Yin JH, Yin J, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu MC, Yu T, Yu XD, Yu YC, Yuan CZ, Yuan J, Yuan J, Yuan L, Yuan SC, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng SH, Zeng X, Zeng Y, Zeng YJ, Zeng YJ, Zhai XY, Zhai YC, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang H, Zhang HC, Zhang HH, Zhang HH, Zhang HQ, Zhang HR, Zhang HY, Zhang J, Zhang J, Zhang JJ, Zhang JL, Zhang JQ, Zhang JS, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang LM, Zhang L, Zhang P, Zhang QY, Zhang RY, Zhang SH, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang Y, Zhang YT, Zhang YH, Zhang YM, Zhang Y, Zhang ZD, Zhang ZH, Zhang ZL, Zhang ZY, Zhang ZY, Zhang ZZ, Zhao G, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao N, Zhao RP, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng BM, Zheng JP, Zheng WJ, Zheng YH, Zhong B, Zhong X, Zhou H, Zhou JY, Zhou LP, Zhou S, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhou ZC, Zhu AN, Zhu J, Zhu K, Zhu KJ, Zhu KS, Zhu L, Zhu LX, Zhu SH, Zhu TJ, Zhu WD, Zhu YC, Zhu ZA, Zou JH, Zu J. Strong and Weak CP Tests in Sequential Decays of Polarized Σ^{0} Hyperons. PHYSICAL REVIEW LETTERS 2024; 133:101902. [PMID: 39303247 DOI: 10.1103/physrevlett.133.101902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/10/2024] [Revised: 07/16/2024] [Accepted: 08/07/2024] [Indexed: 09/22/2024]
Abstract
The J/ψ, ψ(3686)→Σ^{0}Σ[over ¯]^{0} processes and subsequent decays are studied using the world's largest J/ψ and ψ(3686) data samples collected with the BESIII detector. The parity-violating decay parameters of the decays Σ^{0}→Λγ and Σ[over ¯]^{0}→Λ[over ¯]γ, α_{Σ^{0}}=-0.0017±0.0021±0.0018 and α[over ¯]_{Σ^{0}}=0.0021±0.0020±0.0022, are measured for the first time. The strong CP symmetry is tested in the decays of the Σ^{0} hyperons for the first time by measuring the asymmetry A_{CP}^{Σ}=α_{Σ^{0}}+α[over ¯]_{Σ^{0}}=(0.4±2.9±1.3)×10^{-3}. The weak CP test is performed in the subsequent decays of their daughter particles Λ and Λ[over ¯]. Also for the first time, the transverse polarizations of the Σ^{0} hyperons in J/ψ and ψ(3686) decays are observed with opposite directions, and the ratios between the S-wave and D-wave contributions of the J/ψ, ψ(3686)→Σ^{0}Σ[over ¯]^{0} decays are obtained. These results are crucial to understand the decay dynamics of the charmonium states and the production mechanism of the Σ^{0}-Σ[over ¯]^{0} pairs.
Collapse
|
17
|
Acharya S, Adamová D, Aglieri Rinella G, Aglietta L, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Ahuja I, Akindinov A, Al-Turany M, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alocco G, Alt T, Altamura AR, Altsybeev I, Alvarado JR, Anaam MN, Andrei C, Andreou N, Andronic A, Andronov E, Anguelov V, Antinori F, Antonioli P, Apadula N, Aphecetche L, Appelshäuser H, Arata C, Arcelli S, Aresti M, Arnaldi R, Arneiro JGMCA, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Azmi MD, Baba H, Badalà A, Bae J, Baek YW, Bai X, Bailhache R, Bailung Y, Bala R, Balbino A, Baldisseri A, Balis B, Banerjee D, Banoo Z, Barile F, Barioglio L, Barlou M, Barman B, Barnaföldi GG, Barnby LS, Barreau E, Barret V, Barreto L, Bartels C, Barth K, Bartsch E, Bastid N, Basu S, Batigne G, Battistini D, Batyunya B, Bauri D, Bazo Alba JL, Bearden IG, Beattie C, Becht P, Behera D, Belikov I, Bell Hechavarria ADC, Bellini F, Bellwied R, Belokurova S, Beltran LGE, Beltran YAV, Bencedi G, Beole S, Berdnikov Y, Berdnikova A, Bergmann L, Besoiu MG, Betev L, Bhaduri PP, Bhasin A, Bhat MA, Bhattacharjee B, Bianchi L, Bianchi N, Bielčík J, Bielčíková J, Bigot AP, Bilandzic A, Biro G, Biswas S, Bize N, Blair JT, Blau D, Blidaru MB, Bluhme N, Blume C, Boca G, Bock F, Bodova T, Boi S, Bok J, Boldizsár L, Bombara M, Bond PM, Bonomi G, Borel H, Borissov A, Borquez Carcamo AG, Bossi H, Botta E, Bouziani YEM, Bratrud L, Braun-Munzinger P, Bregant M, Broz M, Bruno GE, Buckland MD, Budnikov D, Buesching H, Bufalino S, Buhler P, Burmasov N, Buthelezi Z, Bylinkin A, Bysiak SA, Cabanillas Noris JC, Cai M, Caines H, Caliva A, Calvo Villar E, Camacho JMM, Camerini P, Canedo FDM, Cantway SL, Carabas M, Carballo AA, Carnesecchi F, Caron R, Carvalho LAD, Castillo Castellanos J, Catalano F, Cattaruzzi S, Ceballos Sanchez C, Cerri R, Chakaberia I, Chakraborty P, Chandra S, Chapeland S, Chartier M, Chattopadhyay S, Chattopadhyay S, Cheng T, Cheshkov C, Chibante Barroso V, Chinellato DD, Chizzali ES, Cho J, Cho S, Chochula P, Choudhury D, Christakoglou P, Christensen CH, Christiansen P, Chujo T, Ciacco M, Cicalo C, Ciupek MR, Clai G, Colamaria F, Colburn JS, Colella D, Colocci M, Concas M, Conesa Balbastre G, Conesa Del Valle Z, Contin G, Contreras JG, Coquet ML, Cortese P, Cosentino MR, Costa F, Costanza S, Cot C, Crkovská J, Crochet P, Cruz-Torres R, Cui P, Dainese A, Danisch MC, Danu A, Das P, Das P, Das S, Dash AR, Dash S, De Caro A, de Cataldo G, de Cuveland J, De Falco A, De Gruttola D, De Marco N, De Martin C, De Pasquale S, Deb R, Del Grande R, Dello Stritto L, Deng W, Dhankher P, Di Bari D, Di Mauro A, Diab B, Diaz RA, Dietel T, Ding Y, Ditzel J, Divià R, Dixit DU, Djuvsland Ø, Dmitrieva U, Dobrin A, Dönigus B, Dubinski JM, Dubla A, Dudi S, Dupieux P, Durkac M, Dzalaiova N, Eder TM, Ehlers RJ, Eisenhut F, Ejima R, Elia D, Erazmus B, Ercolessi F, Espagnon B, Eulisse G, Evans D, Evdokimov S, Fabbietti L, Faggin M, Faivre J, Fan F, Fan W, Fantoni A, Fasel M, Feliciello A, Feofilov G, Fernández Téllez A, Ferrandi L, Ferrer MB, Ferrero A, Ferrero C, Ferretti A, Feuillard VJG, Filova V, Finogeev D, Fionda FM, Flatland E, Flor F, Flores AN, Foertsch S, Fokin I, Fokin S, Fragiacomo E, Frajna E, Fuchs U, Funicello N, Furget C, Furs A, Fusayasu T, Gaardhøje JJ, Gagliardi M, Gago AM, Gahlaut T, Galvan CD, Gangadharan DR, Ganoti P, Garabatos C, García Chávez T, Garcia-Solis E, Gargiulo C, Gasik P, Gautam A, Gay Ducati MB, Germain M, Ghimouz A, Ghosh C, Giacalone M, Gioachin G, Giubellino P, Giubilato P, Glaenzer AMC, Glässel P, Glimos E, Goh DJQ, Gonzalez V, Gordeev P, Gorgon M, Goswami K, Gotovac S, Grabski V, Graczykowski LK, Grecka E, Grelli A, Grigoras C, Grigoriev V, Grigoryan S, Grosa F, Grosse-Oetringhaus JF, Grosso R, Grund D, Grunwald NA, Guardiano GG, Guernane R, Guilbaud M, Gulbrandsen K, Gündem T, Gunji T, Guo W, Gupta A, Gupta R, Gupta R, Gwizdziel K, Gyulai L, Hadjidakis C, Haider FU, Haidlova S, Haldar M, Hamagaki H, Hamdi A, Han Y, Hanley BG, Hannigan R, Hansen J, Harris JW, Harton A, Hartung MV, Hassan H, Hatzifotiadou D, Hauer P, Havener LB, Hellbär E, Helstrup H, Hemmer M, Herman T, Herrera Corral G, Herrmann F, Herrmann S, Hetland KF, Heybeck B, Hillemanns H, Hippolyte B, Hoffmann FW, Hofman B, Hong GH, Horst M, Horzyk A, Hou Y, Hristov P, Huhn P, Huhta LM, Humanic TJ, Hutson A, Hutter D, Hwang MC, Ilkaev R, Ilyas H, Inaba M, Innocenti GM, Ippolitov M, Isakov A, Isidori T, Islam MS, Ivanov M, Ivanov M, Ivanov V, Iversen KE, Jablonski M, Jacak B, Jacazio N, Jacobs PM, Jadlovska S, Jadlovsky J, Jaelani S, Jahnke C, Jakubowska MJ, Janik MA, Janson T, Ji S, Jia S, Jimenez AAP, Jonas F, Jones DM, Jowett JM, Jung J, Jung M, Junique A, Jusko A, Kaewjai J, Kalinak P, Kalteyer AS, Kalweit A, Karasu Uysal A, Karatovic D, Karavichev O, Karavicheva T, Karczmarczyk P, Karpechev E, Karwowska MJ, Kebschull U, Keidel R, Keijdener DLD, Keil M, Ketzer B, Khade SS, Khan AM, Khan S, Khanzadeev A, Kharlov Y, Khatun A, Khuntia A, Khuranova Z, Kileng B, Kim B, Kim C, Kim DJ, Kim EJ, Kim J, Kim J, Kim J, Kim M, Kim S, Kim T, Kimura K, Kirsch S, Kisel I, Kiselev S, Kisiel A, Kitowski JP, Klay JL, Klein J, Klein S, Klein-Bösing C, Kleiner M, Klemenz T, Kluge A, Kobdaj C, Kollegger T, Kondratyev A, Kondratyeva N, Konig J, Konigstorfer SA, Konopka PJ, Kornakov G, Korwieser M, Koryciak SD, Kotliarov A, Kovacic N, Kovalenko V, Kowalski M, Kozhuharov V, Králik I, Kravčáková A, Krcal L, Krivda M, Krizek F, Krizkova Gajdosova K, Kroesen M, Krüger M, Krupova DM, Kryshen E, Kučera V, Kuhn C, Kuijer PG, Kumaoka T, Kumar D, Kumar L, Kumar N, Kumar S, Kundu S, Kurashvili P, Kurepin A, Kurepin AB, Kuryakin A, Kushpil S, Kuskov V, Kutyla M, Kweon MJ, Kwon Y, La Pointe SL, La Rocca P, Lakrathok A, Lamanna M, Landou AR, Langoy R, Larionov P, Laudi E, Lautner L, Lavicka R, Lea R, Lee H, Legrand I, Legras G, Lehrbach J, Lelek TM, Lemmon RC, León Monzón I, Lesch MM, Lesser ED, Lévai P, Li X, Liang-Gilman BE, Lien J, Lietava R, Likmeta I, Lim B, Lim SH, Lindenstruth V, Lindner A, Lippmann C, Liu DH, Liu J, Liveraro GSS, Lofnes IM, Loizides C, Lokos S, Lömker J, Loncar P, Lopez X, López Torres E, Lu P, Lugo FV, Luhder JR, Lunardon M, Luparello G, Ma YG, Mager M, Maire A, Majerz EM, Makariev MV, Malaev M, Malfattore G, Malik NM, Malik QW, Malik SK, Malinina L, Mallick D, Mallick N, Mandaglio G, Mandal SK, Manko V, Manso F, Manzari V, Mao Y, Marcjan RW, Margagliotti GV, Margotti A, Marín A, Markert C, Martinengo P, Martínez MI, Martínez García G, Martins MPP, Masciocchi S, Masera M, Masoni A, Massacrier L, Massen O, Mastroserio A, Matonoha O, Mattiazzo S, Matyja A, Mayer C, Mazuecos AL, Mazzaschi F, Mazzilli M, Mdhluli JE, Melikyan Y, Menchaca-Rocha A, Mendez JEM, Meninno E, Menon AS, Meres M, Miake Y, Micheletti L, Mihaylov DL, Mikhaylov K, Miśkowiec D, Modak A, Mohanty B, Khan MM, Molander MA, Monira S, Mordasini C, Moreira De Godoy DA, Morozov I, Morsch A, Mrnjavac T, Muccifora V, Muhuri S, Mulligan JD, Mulliri A, Munhoz MG, Munzer RH, Murakami H, Murray S, Musa L, Musinsky J, Myrcha JW, Naik B, Nambrath AI, Nandi BK, Nania R, Nappi E, Nassirpour AF, Nath A, Nattrass C, Naydenov MN, Neagu A, Negru A, Nekrasova E, Nellen L, Nepeivoda R, Nese S, Neskovic G, Nicassio N, Nielsen BS, Nielsen EG, Nikolaev S, Nikulin S, Nikulin V, Noferini F, Noh S, Nomokonov P, Norman J, Novitzky N, Nowakowski P, Nyanin A, Nystrand J, Oh S, Ohlson A, Okorokov VA, Oleniacz J, Onnerstad A, Oppedisano C, Ortiz Velasquez A, Otwinowski J, Oya M, Oyama K, Pachmayer Y, Padhan S, Pagano D, Paić G, Paisano-Guzmán S, Palasciano A, Panebianco S, Park H, Park H, Park J, Parkkila JE, Patley Y, Paul B, Paulino MMDM, Pei H, Peitzmann T, Peng X, Pennisi M, Perciballi S, Peresunko D, Perez GM, Pestov Y, Petrov V, Petrovici M, Pezzi RP, Piano S, Pikna M, Pillot P, Pinazza O, Pinsky L, Pinto C, Pisano S, Płoskoń M, Planinic M, Pliquett F, Poghosyan MG, Polichtchouk B, Politano S, Poljak N, Pop A, Porteboeuf-Houssais S, Pozdniakov V, Pozos IY, Pradhan KK, Prasad SK, Prasad S, Preghenella R, Prino F, Pruneau CA, Pshenichnov I, Puccio M, Pucillo S, Pugelova Z, Qiu S, Quaglia L, Ragoni S, Rai A, Rakotozafindrabe A, Ramello L, Rami F, Rancien TA, Rasa M, Räsänen SS, Rath R, Rauch MP, Ravasenga I, Read KF, Reckziegel C, Redelbach AR, Redlich K, Reetz CA, Regules-Medel HD, Rehman A, Reidt F, Reme-Ness HA, Rescakova Z, Reygers K, Riabov A, Riabov V, Ricci R, Richter M, Riedel AA, Riegler W, Riffero AG, Ristea C, Rodriguez MV, Rodríguez Cahuantzi M, Rodríguez Ramírez SA, Røed K, Rogalev R, Rogochaya E, Rogoschinski TS, Rohr D, Röhrich D, Rojas PF, Rojas Torres S, Rokita PS, Romanenko G, Ronchetti F, Rosano A, Rosas ED, Roslon K, Rossi A, Roy A, Roy S, Rubini N, Ruggiano D, Rui R, Russek PG, Russo R, Rustamov A, Ryabinkin E, Ryabov Y, Rybicki A, Rytkonen H, Ryu J, Rzesa W, Saarimaki OAM, Sadhu S, Sadovsky S, Saetre J, Šafařík K, Saha P, Saha SK, Saha S, Sahoo B, Sahoo R, Sahoo S, Sahu D, Sahu PK, Saini J, Sajdakova K, Sakai S, Salvan MP, Sambyal S, Samitz D, Sanna I, Saramela TB, Sarkar D, Sarma P, Sarritzu V, Sarti VM, Sas MHP, Sawan S, Scapparone E, Schambach J, Scheid HS, Schiaua C, Schicker R, Schlepper F, Schmah A, Schmidt C, Schmidt HR, Schmidt MO, Schmidt M, Schmidt NV, Schmier AR, Schotter R, Schröter A, Schukraft J, Schweda K, Scioli G, Scomparin E, Seger JE, Sekiguchi Y, Sekihata D, Selina M, Selyuzhenkov I, Senyukov S, Seo JJ, Serebryakov D, Serkin L, Šerkšnytė L, Sevcenco A, Shaba TJ, Shabetai A, Shahoyan R, Shangaraev A, Sharma B, Sharma D, Sharma H, Sharma M, Sharma S, Sharma S, Sharma U, Shatat A, Sheibani O, Shigaki K, Shimomura M, Shin J, Shirinkin S, Shou Q, Sibiriak Y, Siddhanta S, Siemiarczuk T, Silva TF, Silvermyr D, Simantathammakul T, Simeonov R, Singh B, Singh B, Singh K, Singh R, Singh R, Singh R, Singh S, Singh VK, Singhal V, Sinha T, Sitar B, Sitta M, Skaali TB, Skorodumovs G, Slupecki M, Smirnov N, Snellings RJM, Solheim EH, Song J, Sonnabend C, Sonneveld JM, Soramel F, Soto-Hernandez AB, Spijkers R, Sputowska I, Staa J, Stachel J, Stan I, Steffanic PJ, Stiefelmaier SF, Stocco D, Storehaug I, Stratmann P, Strazzi S, Sturniolo A, Stylianidis CP, Suaide AAP, Suire C, Sukhanov M, Suljic M, Sultanov R, Sumberia V, Sumowidagdo S, Szarka I, Szymkowski M, Taghavi SF, Taillepied G, Takahashi J, Tambave GJ, Tang S, Tang Z, Tapia Takaki JD, Tapus N, Tarasovicova LA, Tarzila MG, Tassielli GF, Tauro A, Tavira García A, Tejeda Muñoz G, Telesca A, Terlizzi L, Terrevoli C, Thakur S, Thomas D, Tikhonov A, Tiltmann N, Timmins AR, Tkacik M, Tkacik T, Toia A, Tokumoto R, Tomohiro K, Topilskaya N, Toppi M, Tork T, Torres VV, Torres Ramos AG, Trifiró A, Triolo AS, Tripathy S, Tripathy T, Trogolo S, Trubnikov V, Trzaska WH, Trzcinski TP, Tumkin A, Turrisi R, Tveter TS, Ullaland K, Ulukutlu B, Uras A, Urioni M, Usai GL, Vala M, Valle N, van Doremalen LVR, van Leeuwen M, van Veen CA, van Weelden RJG, Vande Vyvre P, Varga D, Varga Z, Vargas Torres P, Vasileiou M, Vasiliev A, Vázquez Doce O, Vazquez Rueda O, Vechernin V, Vercellin E, Vergara Limón S, Verma R, Vermunt L, Vértesi R, Verweij M, Vickovic L, Vilakazi Z, Villalobos Baillie O, Villani A, Vinogradov A, Virgili T, Virta MMO, Vislavicius V, Vodopyanov A, Volkel B, Völkl MA, Voloshin SA, Volpe G, von Haller B, Vorobyev I, Vozniuk N, Vrláková J, Wan J, Wang C, Wang D, Wang Y, Wang Y, Wegrzynek A, Weiglhofer FT, Wenzel SC, Wessels JP, Wiechula J, Wikne J, Wilk G, Wilkinson J, Willems GA, Windelband B, Winn M, Wright JR, Wu W, Wu Y, Xiong Z, Xu R, Yadav A, Yadav AK, Yalcin S, Yamaguchi Y, Yang S, Yano S, Yeats ER, Yin Z, Yoo IK, Yoon JH, Yu H, Yuan S, Yuncu A, Zaccolo V, Zampolli C, Zanone F, Zardoshti N, Zarochentsev A, Závada P, Zaviyalov N, Zhalov M, Zhang B, Zhang C, Zhang L, Zhang M, Zhang S, Zhang X, Zhang Y, Zhang Z, Zhao M, Zherebchevskii V, Zhi Y, Zhong C, Zhou D, Zhou Y, Zhu J, Zhu Y, Zugravel SC, Zurlo N. Measurements of Chemical Potentials in Pb-Pb Collisions at sqrt[s_{NN}]=5.02 TeV. PHYSICAL REVIEW LETTERS 2024; 133:092301. [PMID: 39270180 DOI: 10.1103/physrevlett.133.092301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/13/2024] [Revised: 03/26/2024] [Accepted: 05/03/2024] [Indexed: 09/15/2024]
Abstract
This Letter presents the most precise measurement to date of the matter-antimatter imbalance at midrapidity in Pb-Pb collisions at a center-of-mass energy per nucleon pair sqrt[s_{NN}]=5.02 TeV. Using the Statistical Hadronization framework, it is possible to obtain the value of the electric charge and baryon chemical potentials, μ_{Q}=-0.18±0.90 MeV and μ_{B}=0.71±0.45 MeV, with unprecedented precision. A centrality-differential study of the antiparticle-to-particle yield ratios of charged pions, protons, Ω baryons, and light (hyper)nuclei is performed. These results indicate that the system created in Pb-Pb collisions at the LHC is on average baryon-free and electrically neutral at midrapidity.
Collapse
|
18
|
Ablikim M, Achasov MN, Adlarson P, Ai XC, Aliberti R, Amoroso A, An MR, An Q, Bai Y, Bakina O, Balossino I, Ban Y, Batozskaya V, Begzsuren K, Berger N, Berlowski M, Bertani M, Bettoni D, Bianchi F, Bianco E, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang TT, Chang WL, Che GR, Chelkov G, Chen C, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SL, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen YQ, Chen ZJ, Cheng WS, Choi SK, Chu X, Cibinetto G, Coen SC, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding B, Ding XX, Ding Y, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du MC, Du SX, Duan ZH, Egorov P, Fan YH, Fang J, Fang SS, Fang WX, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fu CD, Fu JL, Fu YW, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Gramigna S, Greco M, Gu MH, Gu YT, Guan CY, Guan ZL, Guo AQ, Guo LB, Guo MJ, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FHH, Heinz CH, Heng YK, Herold C, Holtmann T, Hong PC, Hou GY, Hou XT, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang XT, Huang YP, Hussain T, Hüsken N, In der Wiesche N, Irshad M, Jackson J, Jaeger S, Janchiv S, Jeong JH, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jia XQ, Jia ZK, Jiang HJ, Jiang PC, Jiang SS, Jiang TJ, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kui X, Kabana S, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kavatsyuk M, Ke BC, Khoukaz A, Kiuchi R, Kliemt R, Kolcu OB, Kopf B, Kuessner M, Kupsc A, Kühn W, Lane JJ, Larin P, Lavania A, Lavezzi L, Lei TT, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li HB, Li HJ, Li HN, Li H, Li JR, Li JS, Li JW, Li KL, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li QX, Li SX, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Li YG, Li ZJ, Li ZX, Liang C, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Liao YP, Libby J, Limphirat A, Lin DX, Lin T, Liu BJ, Liu BX, Liu C, Liu CX, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu LC, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma JL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Ma YM, Maas FE, Maggiora M, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Muskalla J, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu QL, Niu WD, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Patteri P, Pei YP, Pelizaeus M, Peng HP, Peng YY, Peters K, Ping JL, Ping RG, Plura S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Redmer CF, Ren KJ, Rivetti A, Rolo M, Rong G, Rosner C, Ruan SN, Salone N, Sarantsev A, Schelhaas Y, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen WH, Shen XY, Shi BA, Shi HC, Shi JL, Shi JY, Shi QQ, Shi RS, Shi X, Song JJ, Song TZ, Song WM, Song YJ, Song YX, Sosio S, Spataro S, Stieler F, Su YJ, Sun GB, Sun GX, Sun H, Sun HK, Sun JF, Sun K, Sun L, Sun SS, Sun T, Sun WY, Sun Y, Sun YJ, Sun YZ, Sun ZT, Tan YX, Tang CJ, Tang GY, Tang J, Tang YA, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian WH, Tian Y, Tian ZF, Uman I, Wang SJ, Wang B, Wang BL, Wang B, Wang CW, Wang DY, Wang F, Wang HJ, Wang HP, Wang JP, Wang K, Wang LL, Wang M, Wang M, Wang S, Wang S, Wang T, Wang TJ, Wang W, Wang W, Wang WP, Wang X, Wang XF, Wang XJ, Wang XL, Wang Y, Wang YD, Wang YF, Wang YH, Wang YN, Wang YQ, Wang Y, Wang Y, Wang Z, Wang ZL, Wang ZY, Wang Z, Wei D, Wei DH, Weidner F, Wen SP, Wenzel CW, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu C, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu YH, Wu YJ, Wu Z, Xia L, Xian XM, Xiang T, Xiao D, Xiao GY, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu QN, Xu W, Xu WL, Xu XP, Xu YC, Xu ZP, Xu ZS, Yan F, Yan L, Yan WB, Yan WC, Yan XQ, Yang HJ, Yang HL, Yang HX, Yang T, Yang Y, Yang YF, Yang YX, Yang Y, Yang ZW, Yao ZP, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu JS, Yu T, Yu XD, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zeng YJ, Zhai XY, Zhai YC, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang HC, Zhang HH, Zhang HH, Zhang HQ, Zhang HY, Zhang J, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang X, Zhang Y, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZL, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng WJ, Zheng YH, Zhong B, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu L, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou JH, Zu J. Precise Measurement of Born Cross Sections for e^{+}e^{-}→DD[over ¯] at sqrt[s]=3.80-4.95 GeV. PHYSICAL REVIEW LETTERS 2024; 133:081901. [PMID: 39241714 DOI: 10.1103/physrevlett.133.081901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/06/2024] [Revised: 06/24/2024] [Accepted: 07/29/2024] [Indexed: 09/09/2024]
Abstract
Using data samples collected with the BESIII detector at the BEPCII collider at center-of-mass energies ranging from 3.80 to 4.95 GeV, corresponding to an integrated luminosity of 20 fb^{-1}, a measurement of Born cross sections for the e^{+}e^{-}→D^{0}D[over ¯]^{0} and D^{+}D^{-} processes is presented with unprecedented precision. Many clear peaks in the line shape of e^{+}e^{-}→D^{0}D[over ¯]^{0} and D^{+}D^{-} around the mass range of G(3900), ψ(4040), ψ(4160), Y(4260), and ψ(4415), etc., are foreseen. These results offer crucial experimental insights into the nature of hadron production in the open-charm region.
Collapse
|
19
|
Cai L, Jiang C, Zhang G, Fang H, Wang J, Li Y, Xu H, Xiao R, Ding Y, Huang K, Zhang C, Zhang L, Chen B, Duan X, Pan W, Han G, Chen R, Liu L, Zhang S, Tao J, Pang X, Yu J, Wang H, Zhao Y, Li C, Kang X, Qin L, Zhu X, Su J, Li S, Yang C, Feng W, Lei T, Jiang S, Fang R, Lin M, Lu Q, Xu C, Wang W, Zhang J. A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis. Br J Dermatol 2024; 191:336-343. [PMID: 38366639 DOI: 10.1093/bjd/ljae062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Revised: 11/17/2023] [Accepted: 02/10/2024] [Indexed: 02/18/2024]
Abstract
BACKGROUND Xeligekimab (GR1501) is a fully human monoclonal antibody that selectively neutralizes interleukin (IL)-17A and has shown potential efficacy in treating moderate-to-severe psoriasis in preliminary trials. OBJECTIVES To evaluate the efficacy and safety of xeligekimab in Chinese patients with moderate-to-severe psoriasis. METHODS A total of 420 Chinese patients were randomized to 200 mg xeligekimab every 2 weeks (n = 281) or placebo (n = 139) for the first 12 weeks, followed by an extension of the treatment schedule to xeligekimab every 4 weeks for a further 40 weeks. Efficacy was assessed by evaluating achievement of Physician Global Assessment (PGA) 0/1 and 75%, 90% and 100% improvement in Psoriasis Area and Severity Index (PASI 75, PASI 90 and PASI 100, respectively). The safety profile was also evaluated. RESULTS At week 12, PASI 75, PASI 90 and PASI 100 were achieved in 90.7%, 74.4% and 30.2% of patients in the xeligekimab group vs. 8.6%, 1.4% and 0% of patients in the placebo group, respectively. PGA 0/1 was achieved in 74.4% patients in the xeligekimab group and 3.6% of patients in the placebo group. PASI 75 and PGA 0/1 were maintained until week 52. No unexpected adverse events were recorded. CONCLUSIONS Xeligekimab showed high efficacy and was well tolerated in Chinese patients with moderate-to-severe plaque psoriasis.
Collapse
|
20
|
Gao DL, Tian MM, Li L, Zhang M, Wang ZY, Su YB, Jin T, Liu BY, Ding Y. [Primary malignant perivascular epithelioid cell tumors with TFE3 rearrangement of bone: a clinicopathological analysis of two cases]. ZHONGHUA BING LI XUE ZA ZHI = CHINESE JOURNAL OF PATHOLOGY 2024; 53:852-854. [PMID: 39103270 DOI: 10.3760/cma.j.cn112151-20240422-00265] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 08/07/2024]
|
21
|
Lu J, Yu Q, Huang D, Hu Y, Zhong X, Zheng J, Ding Y, Gao Y, Li Y, Shi Y. Spesolimab rapidly treats generalized pustular psoriasis and improves the skin immune microenvironment in Chinese patients. Clin Immunol 2024; 265:110280. [PMID: 38880199 DOI: 10.1016/j.clim.2024.110280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2024] [Revised: 05/15/2024] [Accepted: 06/10/2024] [Indexed: 06/18/2024]
|
22
|
Sheng R, Zheng B, Zhang Y, Sun W, Yang C, Ding Y, Zhou J, Zeng M. "Very early" intrahepatic cholangiocarcinoma (≤ 2.0 cm): MRI manifestation and prognostic potential. Clin Radiol 2024; 79:608-617. [PMID: 38789332 DOI: 10.1016/j.crad.2024.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2024] [Revised: 04/10/2024] [Accepted: 05/02/2024] [Indexed: 05/26/2024]
Abstract
AIMS To explore the MRI characteristics and clinical outcome of the "very early" intrahepatic cholangiocarcinoma (iCCA) ≤2.0cm. MATERIALS AND METHODS Totally 213 pathologically confirmed iCCAs (44 ≤ 2.0cm and 169 of 2.0-5.0cm) from two institutes were included. Forty-four matching non-iCCA malignancies ≤2.0cm were also enrolled. Recurrence-free survival (RFS) was estimated and compared between iCCAs ≤2.0cm and 2.0-5.0cm. MRI features were analyzed and compared between iCCAs ≤2.0cm and 2.0-5.0cm, as well as between iCCAs ≤2.0cm and non-iCCAs ≤2.0cm. Univariate and multivariate regression analyses were performed to identify independent imaging features for discrimination. An MRI-based diagnostic model for iCCA ≤2.0cm was constructed by incorporating the independent imaging features. RESULTS ICCAs ≤2.0cm had a significantly longer RFS than those of 2.0-5.0cm (log rank P=0.014). Imaging features of homogeneous signal (odds ratio (OR) = 6.677, P<0.001) and lack of vessel invasion (OR=7.56, P<0.001) were more frequently displayed in iCCAs ≤2.0cm compared to iCCAs of 2.0-5.0cm independently. In the small lesions ≤2.0cm, imaging features of progressive or persistent enhancement pattern (OR=27.78, P=0.002) and rim diffusion restriction (OR=5.70, P=0.027) were independent imaging features suggestive of iCCA over non-iCCA malignancy; their combination yielded an area under the curve value of 0.824, with a sensitivity of 97.73%. CONCLUSION The "very early" iCCA ≤2.0cm was associated with a favorable outcome after surgery, it displayed different and relatively atypical imaging manifestations compared with those of 2.0-5.0cm. Furthermore, in the small lesions ≤ 2.0cm, MRI can be served as a useful non-invasive diagnostic tool for iCCA in clinical screening with high sensitivity.
Collapse
|
23
|
Wu Y, Yang M, Fan J, Peng Y, Deng L, Ding Y, Yang R, Zhou J, Miao D, Fu Q. Correction to: Deficiency of osteoblastic Arl6ip5 impaired osteoblast differentiation and enhanced osteoclastogenesis via disturbance of ER calcium homeostasis and induction of ER stress-mediated apoptosis. Cell Death Dis 2024; 15:550. [PMID: 39085230 PMCID: PMC11291709 DOI: 10.1038/s41419-024-06858-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/02/2024]
|
24
|
Chen R, Zhong X, Huang D, Chen Z, Yu Y, Lu J, Wang Q, Kong L, Yi X, Zhao Y, Ding Y, Guo L, Shi Y. Advantages of ultrasound imaging for the early diagnosis of psoriatic arthritis in patients with moderate to severe psoriasis. Heliyon 2024; 10:e34136. [PMID: 39055795 PMCID: PMC11269902 DOI: 10.1016/j.heliyon.2024.e34136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2024] [Revised: 07/02/2024] [Accepted: 07/03/2024] [Indexed: 07/28/2024] Open
Abstract
Background Psoriatic arthritis (PsA) is an immune-mediated form of chronic inflammatory arthritis associated with psoriasis (PsO). It constitutes a significant comorbidity of PsO and is distinguished by the presence of widespread musculoskeletal inflammation. Objective The aim of this study is to precisely detect asymptomatic PsA using ultrasound (US) examinations and to distinguish between various stages of PsO. Methods All patients with moderate-to-severe PsO, who consented to undergo musculoskeletal US examinations during their hospitalization between September 2020 and January 2022, were enrolled in the study. We compared patients' demographic characteristics, comorbidities, disease duration, relevant laboratory parameters, and musculoskeletal US findings. Results A total of 547 patients with PsO were included in the study, and 114 of them received a diagnosis of PsA. Furthermore, 16.45 % of patients with moderate to severe PsO displayed subclinical PsA. We observed a significantly higher frequency of abnormal US findings in patients with PsA compared to those without PsA, with a sensitivity of 95.61 % and a specificity of 79.22 %. Additionally, the incidence of enthesitis and synovitis varied significantly between PsA and non-PsA patients, and they were identified as independent variables predicting the presence of PsA. Furthermore, the interphalangeal joint, knee joint, and calcaneal tendon were the most frequently affected areas in PsA, as indicated by the observed US changes. Conclusion Ultrasound examination proves to be a valuable tool for detecting subclinical PsA, facilitating early screening of the condition. Particular attention should be directed towards changes in the interphalangeal joint, knee joint, and calcaneal tendon when reviewing ultrasound images of asymptomatic patients.
Collapse
|
25
|
Zheng J, Ding Y, Chen Y, Shi Y, Gao Y. Effectiveness of baricitinib in acquired reactive perforating collagenosis: a case report. Front Immunol 2024; 15:1388274. [PMID: 39076971 PMCID: PMC11284048 DOI: 10.3389/fimmu.2024.1388274] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2024] [Accepted: 06/21/2024] [Indexed: 07/31/2024] Open
Abstract
Background Acquired reactive perforating collagenosis (ARPC) poses a clinical challenge with an unclear pathogenesis. This disease has been frequently proven resistant to immunosuppressive treatments, significantly affecting the quality of life of patients. In this report, we highlight the efficacy of baricitinib as a viable option for maintenance therapy in ARPC. Case summary An 81-year-old woman presented to our hospital with recurrent pruritus and cup-like ulcerated lesions on her trunk and limbs persisting for 1 year. She exhibited limited response to oral antihistamines and topical steroids. Past medical history revealed a prolonged history of coronary heart disease and type 2 diabetes spanning several years to decades. Histopathological examination revealed cup-shaped depressions filled with necrotic inflammatory debris. In the dermis, a mixed inflammatory infiltrate composed of lymphocytes and histiocytes was observed. Van Gieson staining indicated the elimination of fibrous tissue extending from the dermis into the epidermis. Consequently, a diagnosis of ARPC was established. Due to the inadequate response to conventional treatments and the severe itching, we initiated baricitinib therapy for ARPC, resulting in gradual symptom improvement. Follow-up assessments showed no adverse reactions and normal laboratory findings. Conclusion The case report suggests that baricitinib might offer significant therapeutic benefits for ARPC.
Collapse
|